SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this mechanistic clinical trial is to learn about the effects of medications called soluble guanylyl cyclase stimulators on vascular function and markers of kidney and brain injury in patients having heart surgery. The main questions it aims to answer are: 1. Does soluble guanylyl cyclase stimulation improve blood vessel function compared to placebo? 2. Does soluble guanylyl cyclase stimulation decrease markers of kidney injury and brain injury compared to placebo? Participants will be randomized to a soluble guanylyl cyclase stimulator called vericiguat or placebo, and researchers will compare vascular function and markers of brain and kidney injury to see if vericiguat improves vascular function and reduces markers of injury. This will provide important information to determine the underlying reasons that patients have some kidney and brain function problems after having heart surgery.
Sponsor: Vanderbilt University Medical Center
You may qualify if…
- ✓ 1. Age ≥18 years
- ✓ 2. Elective open-heart surgery, defined as surgery on the heart or aorta that requires sternotomy or thoracotomy
You may not qualify if…
- ✕ 1. Intolerance to vericiguat
- ✕ 2. Use of other soluble guanylyl cyclase stimulators or current use of phosphodiesterase-5 inhibitors
- ✕ 3. Pregnancy or breast feeding. Pregnancy will be excluded in women of child-bearing potential by a urine or serum beta hcg test
- ✕ 4. Renal replacement therapy within 30 days prior to screening
- ✕ 5. Estimated glomerular filtration rate \<15 ml/min per 1.73 m2 per Chronic Kidney Disease Epidemiology collaboration (CKD-EPI) equation at time of screening
- ✕ 6. Systolic blood pressure less than 120 mmHg at the time of screening
- ✕ 7. Prior kidney transplantation
- ✕ 8. History of significant liver dysfunction (defined as Child-Pugh class C)
Where it's recruiting
Nashville
Source: ClinicalTrials.gov · NCT05812755 · last updated 2026-08-06